Orally Bioavailable Competitive CCR5 Antagonists

Journal of Medicinal Chemistry

Volumn 47, Issue 8, 2004, Pages 1939-1955

  Thoma, Gebhard ^a   Nuninger, François ^a   Schaefer, Marc ^a   Akyel, Kayhan G ^a   Albert, Rainer ^a   Beerli, Christian ^a   Bruns, Christian ^a   Francotte, Eric ^a   Luyten, Marcel ^a   MacKenzie, Duncan ^a   Oberer, Lukas ^a   Streiff, Markus B ^a   Wagner, Trixie ^a   Walter, Hansrudolf ^a   Weckbecker, Gisbert ^a   Zerwes, Hans Guenter ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

(4,6 DIMETHYL 1 OXOPYRIMIDIN 5 YL)(4 DIPHENYLAMINO 4' METHYL [1,4']BIPIPERIDINYL 1' YL)METHANONE; [4 (BENZYLPHENYLAMINO) 4' METHYL [1,4']BIPIPERIDINYL 1' YL](2,4 DIMETHYL 1 OXOPYRIDIN 3 YL)METHANONE; CHEMOKINE RECEPTOR CCR5; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOIMMUNE DISEASE; CALCIUM MOBILIZATION; CELL MIGRATION; CHEMICAL MODIFICATION; CHO CELL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMULUS LUPULUS; IC 50; INFLAMMATION; KIDNEY ALLOGRAFT REJECTION; LIGAND BINDING; MONOCYTE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALCIUM; CELL LINE; CHEMOTAXIS, LEUKOCYTE; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; DIPHENYLAMINE; HUMANS; LYMPHOCYTES; MACACA FASCICULARIS; MICE; MOLECULAR STRUCTURE; PYRIMIDINONES; RADIOLIGAND ASSAY; RATS; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 11144357557     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031046g     Document Type: Article

References (56)

1. Murphy, P. M.; Baggiolini, M.; Charo, I. F.; Hebert, C. A.; Horuk, R.; Matsushima, K.; Miller, L. H.; Oppenheim, J. J.; Power, C. A. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000, 52, 145-176.
2. (b) Moser, B.; Loetscher, P. Lymphocyte traffic control by chemokines. Nat. Immunol. 2001, 2, 123-128.
3. (a) Loetscher, P.; Uguccioni, M.; Bordoli, L.; Baggiolini, M.; Moser, B. ; Chizzolini, C.; Dayer, J. M. CCR5 is characteristic of Th1 lymphocytes. Nature 1998, 391, 344-345.
4. (b) Kim, C. H.; Rott, L.; Kunkel, E. J.; Genovese, M. C.; Andrew, D. P.; Wu, L.; Butcher, E. C. Rules of chemokine receptor association with T cell polarization in vivo. J. Clin. Invest 2001, 108, 1331-1339.
5. (c) Kunkel, E. J.; Boisvert, J.; Murphy, K.; Vierra, M. A.; Genovese, M. C.; Wardlaw, A. J.; Greenberg, H. B.; Hodge, M. R.; Wu, L.; Butcher, E. C.; Campbell, J. J. Expression of the Chemokine Receptors CCR4, CCR5, and CXCR3 by Human Tissue-Infiltrating Lymphocytes. Am. J. Pathol. 2002, 160, 347-355.
6. (a) Kaufmann, A.; Salentin, R.; Gemsa, D.; Sprenger, H. Increase of CCR1 and CCR5 expression and enhanced functional response to MIP-1 alpha during differentiation of human monocytes to macrophages. J. Leukoc. Biol. 2001, 69, 248-252.
7. (b) Weber, C.; Belge, K. U.; von Hundelshausen, P.; Draude, G.; Steppich, B.; Mack, M.; Frankenberger, M.; Weber, K. S.; Ziegler-Heitbrock, H. W. Differential chemokine receptor expression and function in human monocyte subpopulations. J. Leukoc. Biol. 2000, 67, 699-704.
8. (c) Lee, B.; Sharron, M.; Montaner, L. J.; Weissman, D.; Doms, R. W. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 5215-5220.
9. (d) Tuttle, D. L.; Harrison, J. K.; Anders, C.; Sleasman, J. W.; Goodenow, M. M. Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J. Virol. 1998, 72, 4962-4969.
10. Detheux, M.; Standker, L.; Vakili, J.; Munch, J.; Forssmann, U.; Adermann, K.; Pohlmann, S.; Vassart, G.; Kirchhoff, F.; Parmentier, M.; Forssmann, W. G. Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J. Exp. Med. 2000, 192, 1501-1508.
11. Berger, E. A.; Murphy, P. M.; and Farber, J. M. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 1999, 17, 657-700.
12. (a) Maeda, K.; Yoshimura, K.; Shibayama, S.; Habashita, H.; Tada, H.; Sagawa, K.; Miyakawa, T.; Aoki, M.; Fukushima, D. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effect on CCR5. J. Biol. Chem. 2001, 276, 35194-35200.
13. (b) Shiraishi, M.; Aramaki, Y.; Seto, M.; Imoto, H.; Nishikawa, Y.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Nishimura, O.; Baba, M.; Fujino, M. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J. Med. Chem. 2000, 43, 2049-2063.
14. (c) Shiraishi, M.; Baba, M.; Aramaki, Y.; Nishimura, O.; Kanzaki, N. Quarternary ammonium salts and their use. Patent WO001-0965, 2000.
15. (d) Shiraishi, M.; Baba, M.; Seto, M.; Kanzaki, N.; Nishimura, O. Benzothiepin-anilide derivatives, their production and their use for antagonizing CCR-5. Patent WO0037455, 2000.
16. (e) Dorn, C. P.; Finke, P. E.; Oates, B.; Budhu, R. J.; Mills, S. G.; MacCoss, M.; Malkowitz, L.; Springer, M. S.; Daugherty, B. L.; Gould, S. L.; DeMartinio, J. A.; Siciliano, S. J.; Carella, A.; Carver, G.; Holmes, K.; Danzeisen, R.; Hazuda, D.; Kessler, J.; Lineberger, J.; Miller, M.; Schleif, W. A.; Emini, E. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 2001, 11, 259-264.
17. (f) Finke, P. E.; Meurer, L. C.; Oates, B.; Mills, S. G.; MacCoss, M.; Malkowitz, L.; Springer, M. S.; Daugherty, B. L.; Gould, S. L.; DeMartinio, J. A.; Siciliano, S. J.; Carella, A.; Carver, G.; Holmes, K.; Danzeisen, R.; Hazuda, D.; Kessler, J.; Lineberger, J.; Miller, M.; Schleif, W. A.; Emini, E. A. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[n-(methyl)-n-(phenylsulfonyl)amino]-4-(piperidin-1-yl)-butanes. Bioorg. Med. Chem. Lett. 2001, 11, 265-270.
18. (g) Hale, J. H.; Budhu, R. J.; Mills, S. G.; MacCoss, M.; Malkowitz, L.; Siciliano, S. J.; Gould, S. L.; DeMartinio, J. A.; Springer, M. S. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: Discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. Bioorg. Med. Chem. Lett. 2001, 11, 1437-1440.
19. (h) Hale, J. H.; Budhu, R. J.; Holson, E. B.; Finke, P. E.; Oates, B.; Mills, S. G.; MacCoss, M.; Gould, S. L.; DeMartinio, J. A.; Springer, M. S.; Siciliano, S. J.; Malkowitz, L.; Schleif, W. A.; Hazuda, D.; Miller, M.; Kessler, J.; Danzeisen, R.; Holmes, K.; Lineberger, J.; Carella, A.; Carver, G. ; Emini, E.A. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity. Bioorg. Med. Chem. Lett. 2001, 11, 2741-2745.
20. (i) Bondinell, W. E. Propenamides as CCR5 modulators. Patent WO0006153, 2000.
21. (j) Ku, T. W.; Bondinell, W. E.; Neeb, M. J. Substituted anilide compounds and methods. Patent WO0006146, 2000.
22. (k) Bondinell, W. E.; Neeb, M. J. Novel azaheterocyclylcarboxamide derivatives useful as CCR-5 agonists, antagonists and modulators. Patent WO0205819, 2002.
23. (l) Perros, M.; Price, D. A.; Stammen, B. L. C.; Wood, A. Tropane Derivatives Useful in Therapy. Patent WO0190106, 2001.
24. (l) Armour, D. R.; Price, D. A.; Stammen, B. L. C.; Wood, A.; Perros, M. ; Edwards, M. P. Azabicycloalkanes as CCR5 modulators. Patent WO0038680, 2000.
25. (m) Basford, P. A.; Stephenson, P. T.; Taylor, S. C. J.; Wood, A. Tropane derivatives as CCR5 modulators. Patent WO003084954, 2003.
26. (n) Burrows, J.; Cumming, J.; McInally, T. Novel benzimidazole or benzotriazole derivatives for treating CCR5-mediated diseases such as respiratory and infectious disorders. Patent WO0166525, 2001.
27. (o) Burrows, J.; Cooper, A.; Cumming, J.; McInally, T.; Tucker, H. Novel 4-aminopiperidine modulators of chemokine receptor activity. Patent WO0187839, 2001.
28. (p) Burrows, J.; Cumming, J.; Tucker, H. N-4-piperidinyl compounds as CCR5 modulators. Patent WO02070479, 2002.
29. (q) Burrows, J.; Cumming, J. Novel 3-[4-(phenylacetylamino)piperidin-1-yl]propane derivatives as chemokine receptor modulators useful for treating immune and inflammatory disorders and HIV infection. Patent WO02079156, 2002.
30. (r) Cumming, J. Novel piperidine derivatives modulators of chemokine receptors. Patent WO03042178, 2003.
31. (s) Edlin, C. D.; Redshaw, S.; Smith, I. E. D.; Walter, D. S. Aminopiperidine derivatives which prevent HIV cell entry by blocking the interaction of HIV gp 120 with CCR5. Patent WO02079186, 2002.
32. (t) Kazmierski, W.; Bifulco, N.; Yang, H.; Boone, L.; DeAnda, F.; Watson, C.; Kenakin, T. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg. Med. Chem. 2003, 11, 2663-2676.
33. (u) Gao, Z.; Metz, W. A. Unraveling the chemistry of chemokine receptor ligands. Chem. Rev. 2003, 103, 3733-3752.
34. (a) Strizki, J. M.; Xu, S.; Wagner, N. E.; Wojcik, L.; Liu, J.; Hou, Y.; Endres, M.; Palani, A.; Shapiro, S.; Clader, J. W.; Greenlee, W. J.; Tagat, J. R.; McCombie, S.; Cox, K.; Fawzi, Ahmad B.; Chou, C.-C.; Pugliese-Sivo, C.; Davies, L.; Moreno, M. E.; Ho, D. D.; Trkola, A.; Stoddart, C. A.; Moore, J. P. ; Reyes, G. R.; Baroudy, B. M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 12718-12723.
35. (b) Palani, A.; Shapiro, S.; Clader, J. W.; Greenlee, W. J.; Cox, K.; Strizki, J.; Endres, M.; Baroudy, B. M. Discovery of 4-[(Z)-(4-Bromophenyl)-(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3-pyridinyl) carbonyl]-4′-methyl-1,4′-bipiperidine N-Oxide (SCH 351125): An Orally Bioavailable Human CCR5 Antagonist for the Treatment of HIV Infection. J. Med. Chem. 2001, 44, 3339-3342.
36. (c) Palani, A.; Shapiro, S.; Josien, H.; Bara, T.; Clader, J. W.; Greenlee, W. J.; Cox, K.; Strizki, J. M.; Baroudy, B. M. Synthesis, SAR, and Biological Evaluation of Oximino-Piperidino-Piperidine Amides. 1. Orally Bioavailable CCR5 Receptor Antagonists with Potent Anti-HIV Activity. J. Med. Chem. 2002, 45, 3143-3160.
37. (d) Tagat, J. R.; Steensma, R. W.; McCombie, S. W.; Nazareno, D. V.; Lin, S.-I.; Neustadt, B. R.; Cox, K.; Xu, S.; Wojcik, L.; Murray, M. G.; Vantuno, N.; Baroudy, B. M.; Strizki, J. M. Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-Dimethyl-3-pylidinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S) -[4-(trifluoro-methyl)phenyl]ethyl]-1-piperazinyl]-piperidine N1-Oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist. J. Med. Chem. 2001, 44, 3343-3346.
38. (e) McCombie, S. W.; Tagat, J. R.; Vice, S. F.; Lin, S.-I.; Steensma, R. ; Palani, A.; Neustadt, B. R.; Baroudy, B. M.; Strizki, J. M.; Endres, M.; Cox, K.; Dan, N.; Chou, C.-C. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides. Bioorg. Med. Chem. Lett. 2003, 13, 567-571.
39. (f) Tagat, J. R.; McCombie, S. W.; Steensma, R. W.; Lin, S.-I.; Nazareno, D. V.; Baroudy, B.; Vantuno, N.; Xu, S.; Liu, J. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-Methyl piperazine as a key pharmacophore element. Bioorg. Med. Chem. Lett. 2001, 11, 2143-2257.
40. (a) Fischereder, M.; Luckow, B.; Hocher, B.; Wuthrich, R. P.; Rothenpieler, U.; Schneeberger, H.; Panzer, U.; Stahl, R. A.; Hauser, I. A.; Budde, K.; Neumayer, H.; Kramer, B. K.; Land, W.; Schlondorff, D. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001, 357, 1758-1761.
41. (b) Strieter, R. M.; Belperio, J. A. Chemokine receptor polymorphism in transplantation immunology: No longer just important in AIDS. Lancet 2001, 357, 1725-1726.
42. Gao, W.; Faia, K. L.; Csizmadia, V.; Smiley, S. T.; Soler, D.; King, J. A.; Danoff, T. M.; Hancock, W. W. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001, 72, 1199-1205.
43. For reviews on the role of chemokines and their receptors in transplant rejection see (a) DeVries, M. E.; Hosiawa, K. A.; Cameron, C. M.; Bosinger, S. E.; Persad, D.; Kelvin, A. A.; Coombs, J. C.; Wang, H.; Zhong, R.; Cameron, M. J.; Kelvin, D. J. The role of chemokines and chemokine receptors in alloantigen-independent and alloantigen-dependent transplantation injury. Sem. Immunol. 2003, 15, 33-48.
44. (b) Nelson, P. J.; Krensky, A. M. Chemokines, chemokine receptors, and allograft rejection. Immunity 2001, 14, 377-386.
45. (c) Hancock, W. W.; Wang, L.; Ye, Q.; Han, R.; Lee, I. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Cur. Op. Immunol. 2003, 15, 479-486.
46. Abdi, R.; Smith, R. N.; Makhlouf, L.; Najafian, N.; Luster, A. D.; Auchincloss, H. Jr.; Sayegh, M. H. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 2002, 51, 2489-2495.
47. Neither 1a nor any other compound discussed in this report inhibited mouse CCR5 at concentrations up to 1000 nM or higher.
48. Polniaszek, R. P.; Belmont, S. E. Enantioselective total synthesis of indolizidine alkaloids 167B and 209D. J. Org. Chem. 1990, 55, 4688-4693.
49. Gaddum, J. H. Theories of drug antagonism. Pharmacol. Rev. 1957, 9, 211-218.
50. Bleul, C. C.; Wu, L.; Hoxie, J. A.; Springer, T. A.; Mackay, C. R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 1925-1930.
51. 3.
52. (a) Palani, A.; Shapiro, S.; Clader, J. W.; Greenlee, W. J.; Blythin, D. ; Cox, K.; Wagner, N. E.; Strizki, J.; Baroudyc, B. M.; Dand, N. Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist. Bioorg. Med. Chem. Lett. 2003, 13, 705-708.
53. (b) McCombie, S. W.; Tagat, J. R.; Vice, S. F.; Lin, S.-I.; Steensma, R. ; Palani, A.; Neustadt, B. R.; Baroudy, B. M.; Strizki, J. M.; Endres, M.; Cox, K.; Dan N.; Chou, C.-C. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides. Bioorg. Med. Chem. Lett. 2003, 13, 567-571.
54. Spek, A. L. PLATON, a Multi-Purpose Crystallographic Tool; Utrecht University: Utrecht, The Netherlands (http://www.cryst.chem.uu.nl/platon).
55. Sheldrick, G. M. SADABS, version 2.10, University of Göttingen, Göttingen, Germany.
56. Sheldrick, G. M. SHELXTL, version 6.12, Bruker AXS Inc., Madison, WI.